PharmaMar’s Lurbinectedin to Be Marketed as Zepsyre After Approval as Ovarian Cancer Therapy

PharmaMar’s Lurbinectedin to Be Marketed as Zepsyre After Approval as Ovarian Cancer Therapy
Once approved, PharmaMar’s lurbinectedin (PM1183) will be marketed under the brand name Zepsyre as a treatment for solid tumors in ovarian, lung, and breast cancers. Zepsyre is in its final stage of development as an anticancer treatment. Selecting a brand name is part of the approval process by the European Medicines Agency and the U.S. Food and Drug Administration

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *